Лучшие больницы для «Gastrointestinal Stromal Tumor Treatment» в Дели (NCR), Индия

Gastrointestinal Stromal Tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract, arising predominantly from the interstitial cells of Cajal or their precursors. They occur most frequently in the stomach (60%) and small intestine (25%), with the remainder distributed across the colon, rectum, esophagus, and mesentery. Unlike epithelial GI cancers, GISTs are defined by activating mutations in the KIT proto-oncogene (approximately 75–80% of cases), PDGFRA (10–15%), or, in a minority of cases, by NF1 mutations, SDH deficiency, or BRAF alterations. These driver mutations make GIST uniquely susceptible to tyrosine kinase inhibitor (TKI) therapy, fundamentally altering the treatment landscape since 2001.

• CONFIRMED GIST DIAGNOSIS: Patients with histologically confirmed GIST via endoscopic ultrasound-guided fine-needle biopsy (EUS-FNA), CT/MRI-guided core needle biopsy, or surgical specimen with immunohistochemistry positive for CD117 (KIT), DOG1, and/or CD34
• MOLECULAR PROFILING REQUIRED: KIT exon 9, 11, 13, 17 and PDGFRA exon 12, 14, 18 mutational analysis is mandatory before initiating TKI therapy; SDH subunit testing for wild-type GIST
• SURGICAL CANDIDATES: Patients with localized, resectable GIST (ECOG performance status 0–2) without major comorbidities precluding general anesthesia; tumor size and location must be assessed for feasibility of R0 resection
• NEOADJUVANT IMATINIB CANDIDATES: Patients with large (>5 cm), borderline resectable, or anatomically complex tumors (gastroesophageal junction, duodenum, rectum) where preoperative TKI downsizing improves surgical outcomes or enables organ-sparing resection
• METASTATIC/UNRESECTABLE PATIENTS: Patients with hepatic, peritoneal, or distant metastases who are candidates for systemic TKI therapy; may also be candidates for cytoreductive surgery or radiofrequency ablation (RFA) of limited hepatic disease after response to imatinib
• +4 more

Surgical APPROACHES:

Open Resection: Traditional approach for large (>10 cm), adherent, or anatomically complex GISTs. Involves en-bloc resection of the tumor with a 1–2 cm margin of normal tissue. No formal lymph node dissection is required. Gastric wedge resection, segmental small bowel resection, or partial colectomy are the most common procedures depending on the primary site. Careful handling of the pseudocapsule is paramount — rupture during resection converts R0 to R1/R2 status and significantly worsens prognosis.

Laparoscopic / Minimally Invasive Resection: Appropriate for gastric GISTs ≤5 cm and select small intestinal lesions in experienced centers. Techniques include laparoscopic wedge resection using endoscopic stapling devices, laparoscopic-endoscopic cooperative surgery (LECS), and intragastric laparoscopic resection for intraluminal tumors near the cardia or pylorus. Benefits include reduced blood loss, shorter hospital stay (5–7 days vs. 10–14 days for open), and faster return to oral tyrosine kinase therapy.

Robotic-Assisted Surgery: Utilized for GISTs in anatomically challenging locations — gastroesophageal junction, posterior gastric wall, duodenum, and rectum. The da Vinci Surgical System provides enhanced three-dimensional visualization and 7-degree-of-freedom articulation, facilitating precise dissection in confined spaces while minimizing tumor manipulation risk. Available at premium centers in India (Apollo, Fortis, Tata Memorial) and UAE (Cleveland Clinic Abu Dhabi, Mediclinic City Hospital Dubai).

PHASE 1 — PRE-ARRIVAL (2–4 weeks before travel):

• GAF Healthcare case managers review all existing pathology reports, CT/MRI imaging, and molecular profiling results with the receiving oncology team
• Multidisciplinary tumor board (MDT) review including surgical oncology, medical oncology, radiology, and pathology is convened virtually before patient arrival
• E-Medical visa application initiated for India (typically approved within 3–5 business days); UAE visit visa or medical visa arranged as applicable
• Travel itinerary, airport pickup, and accommodation for patient and attendant confirmed

PHASE 2 — ARRIVAL AND WORKUP (Days 1–5):